RecruitingPhase 1NCT05460507

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Studying Glial tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Plus Therapeutics
Principal Investigator
Andrew J Brenner, PhD
The Cancer Therapy and Research Center at UTHSCSA
Intervention
Retreatment Rhenium Liposome(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05460507 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor

← Back to all trials